| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.SJPAIN.2016.09.011 |
| P698 | PubMed publication ID | 28850427 |
| P2093 | author name string | Marie-Claude Fournié-Zaluski | |
| Hervé Poras | |||
| Tanja Ouimet | |||
| Sara González-Rodríguez | |||
| Bernard P Roques | |||
| Ana Baamonde | |||
| Ana Lastra | |||
| Luis Menéndez | |||
| P2860 | cites work | CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids | Q24556619 |
| In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? | Q24564956 | ||
| Facilitation of enkephalins catabolism inhibitor-induced antinociception by drugs classically used in pain management | Q28188715 | ||
| Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7 | Q28270611 | ||
| International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels | Q28289125 | ||
| 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor | Q28369726 | ||
| Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (NaV1.7) levels through activation of protein kinase C in painful diabetic neuropathy | Q28580927 | ||
| Quantitative assessment of tactile allodynia in the rat paw | Q29617366 | ||
| The role of neuroinflammation and neuroimmune activation in persistent pain | Q31889102 | ||
| Bone cancer pain. | Q34120101 | ||
| The chemokine CCL5 induces CCR1-mediated hyperalgesia in mice inoculated with NCTC 2472 tumoral cells | Q34390437 | ||
| A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. | Q34431207 | ||
| Similarities and differences in tumor growth, skeletal remodeling and pain in an osteolytic and osteoblastic model of bone cancer. | Q34559758 | ||
| Protection of endogenous enkephalin catabolism as natural approach to novel analgesic and antidepressant drugs. | Q34602588 | ||
| CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain | Q35162945 | ||
| Combination strategies for pain management | Q35548154 | ||
| Synergistic interactions between cannabinoid and opioid analgesics | Q35620905 | ||
| Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. | Q35678770 | ||
| Pharmacological characterization of the peripheral FAAH inhibitor URB937 in female rodents: interaction with the Abcg2 transporter in the blood‐placenta barrier | Q36476735 | ||
| Cancer pain and its impact on diagnosis, survival and quality of life | Q36599929 | ||
| Prevalence of pain in patients with cancer: a systematic review of the past 40 years | Q36758835 | ||
| P2X3 receptor involvement in pain states | Q36977790 | ||
| A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain | Q37067266 | ||
| Increased anandamide uptake by sensory neurons contributes to hyperalgesia in a model of cancer pain | Q37107118 | ||
| The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain | Q37120771 | ||
| The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms | Q37182268 | ||
| Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer | Q37247455 | ||
| P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs | Q37355653 | ||
| Interaction of the cannabinoid and opioid systems in the modulation of nociception | Q37444813 | ||
| 23. Pain in Patients with Cancer | Q37890476 | ||
| Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain | Q37998313 | ||
| Quantitative Methods for Assessing Drug Synergism | Q38022020 | ||
| Combination pharmacotherapy for management of chronic pain: from bench to bedside | Q38145752 | ||
| Pain and nociception: mechanisms of cancer-induced bone pain | Q38209631 | ||
| Pain without nociceptors? Nav1.7-independent pain mechanisms. | Q38552593 | ||
| Receptome: Interactions between three pain-related receptors or the "Triumvirate" of cannabinoid, opioid and TRPV1 receptors | Q38621176 | ||
| Investigation into the role of P2X(3)/P2X(2/3) receptors in neuropathic pain following chronic constriction injury in the rat: an electrophysiological study | Q38758277 | ||
| Interleukin-21 expanded NKDC in vitro reduces the B16F10 tumor growth in vivo | Q39253393 | ||
| CCL2 released at tumoral level contributes to the hyperalgesia evoked by intratibial inoculation of NCTC 2472 but not B16-F10 cells in mice | Q39279011 | ||
| Chronic administration of the selective P2X3, P2X2/3 receptor antagonist, A-317491, transiently attenuates cancer-induced bone pain in mice | Q39341698 | ||
| Mechanical allodynia and thermal hyperalgesia induced by experimental squamous cell carcinoma of the lower gingiva in rats | Q39346688 | ||
| Functional up-regulation of P2X3 receptors in dorsal root ganglion in a rat model of bone cancer pain. | Q39359860 | ||
| Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study | Q39471539 | ||
| Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain. | Q39727048 | ||
| Involvement of enkephalins in the inhibition of osteosarcoma-induced thermal hyperalgesia evoked by the blockade of peripheral P2X3 receptors | Q39797735 | ||
| Local loperamide inhibits thermal hyperalgesia but not mechanical allodynia induced by intratibial inoculation of melanoma cells in mice | Q39999356 | ||
| Opiate agonist action of antidiarrheal agents in vitro and in vivo?Findings in support for selective action | Q40136730 | ||
| Re-organization of P2X3 receptor localization on epidermal nerve fibers in a murine model of cancer pain. | Q40424547 | ||
| Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. | Q40477180 | ||
| Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system | Q40669501 | ||
| The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel | Q41217429 | ||
| The antinociceptive effects of intrathecally administered SCH32615, an enkephalinase inhibitor in the rat. | Q41232960 | ||
| BRAID: A Unifying Paradigm for the Analysis of Combined Drug Action. | Q41244127 | ||
| Combination Drug Therapy for Pain following Chronic Spinal Cord Injury | Q42548830 | ||
| Activation of the arginine-nitric oxide pathway in primary sensory neurons contributes to dipyrone-induced spinal and peripheral analgesia | Q42553962 | ||
| Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations | Q42618792 | ||
| Long-lasting oral analgesic effects of N-protected aminophosphinic dual ENKephalinase inhibitors (DENKIs) in peripherally controlled pain | Q42702528 | ||
| Systemic blockade of P2X3 and P2X2/3 receptors attenuates bone cancer pain behaviour in rats | Q42923060 | ||
| Unilateral hot plate test: a simple and sensitive method for detecting central and peripheral hyperalgesia in mice | Q43821485 | ||
| The interaction index: a measure of drug synergism | Q44050835 | ||
| Involvement of nitric oxide in the inhibition of bone cancer-induced hyperalgesia through the activation of peripheral opioid receptors in mice | Q44335186 | ||
| Cannabinoid CB1 receptor elevation of intracellular calcium in neuroblastoma SH-SY5Y cells: interactions with muscarinic and delta-opioid receptors | Q44342671 | ||
| Suppression by gabapentin of pain-related mechano-responses in mice given orthotopic tumor inoculation | Q44388900 | ||
| Initial thermal heat hypoalgesia and delayed hyperalgesia in a murine model of bone cancer pain. | Q44390920 | ||
| Reduction in [D-Ala2, NMePhe4, Gly-ol5]enkephalin-induced peripheral antinociception in diabetic rats: the role of the L-arginine/nitric oxide/cyclic guanosine monophosphate pathway | Q44704879 | ||
| Peripheral mechanisms underlying the essential role of P2X3,2/3 receptors in the development of inflammatory hyperalgesia. | Q46199311 | ||
| Antinociceptive and anti-allodynic effects of oral PL37, a complete inhibitor of enkephalin-catabolizing enzymes, in a rat model of peripheral neuropathic pain induced by vincristine | Q46306827 | ||
| Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain | Q46427425 | ||
| Inhibition of osteosarcoma-induced thermal hyperalgesia in mice by the orally active dual enkephalinase inhibitor PL37. Potentiation by gabapentin | Q46436551 | ||
| 3-Oxoisoindoline-1-carboxamides: potent, state-dependent blockers of voltage-gated sodium channel Na(V)1.7 with efficacy in rat pain models | Q48148907 | ||
| P921 | main subject | murine model | Q122890741 |
| P304 | page(s) | 25-38 | |
| P577 | publication date | 2016-11-01 | |
| P1433 | published in | Scandinavian Journal of Pain | Q15817429 |
| P1476 | title | Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets, in a murine model of cancer-induced bone pain | |
| P478 | volume | 14 |
| Q101121087 | A low pKa ligand inhibits cancer-associated pain in mice by activating peripheral mu-opioid receptors |
| Q90185275 | Improved efficacy, tolerance, safety and abuse liability profile of the combination CR4056-morphine over morphine alone in rodent models |
| Q50283834 | Multi-target treatment of bone cancer pain using synergistic combinations of pharmacological compounds in experimental animals |
| Q90626263 | Overexpressed VEPH1 inhibits epithelial-mesenchymal transition, invasion, and migration of human cutaneous melanoma cells through inactivating the TGF-β signaling pathway |
Search more.